Ideaz

Dysmeno - A safe and affordable period cramp relief tablet

“Where Science Meets Comfort.”

The Problem:

• Almost 80% of menstruating women experience cramps ranging from moderate to severe and the current solutions to alleviate this pain are mostly over-the-counter painkillers (NSAIDs, paracetamol) or hormonal interventions (birth control pills), which often have side effects like gastric irritation, liver stress, risk of carcinogenicity and hormonal imbalance.
• High doses of the existing tablets coupled with cumulative dosage and age can increase likelihood of severe and adverse effects to our health.

Gap in the Market:

• Safety: Painkillers that are currently being used by most women today pose multiple risks to their health.
• Accessibility: In many regions, safe and affordable options are inaccessible.

Dysmeno attempts to fill this gap in the following ways:

• Non-carcinogenic & safe: Scientifically formulated to avoid long-term risks.
• Little to no side effects: Gentle on the stomach, liver, and overall metabolism.
• Affordable: Priced to be accessible to women across income groups.
• Fast-acting & effective: Provides relief within a short period.
• Natural + science-backed: Blend of natural extracts and clinically validated compounds to maximize relief and safety.

The Solution? - Dysmeno

• It is a tablet that performs the same functions as that of the existing painkillers without the adverse side effects being subjected to our health.
• Its composition is as follows:

1. Standardized Ginger extract (Zingiber officinale) — 250 mg
2. Fennel (Foeniculum vulgare) extract — 30 mg
3. Curcumin (as phytosome or curcuminoid + piperine complex) — 250–500 mg curcuminoids equiv. + 5 mg piperine
4. Magnesium (elemental Mg as magnesium citrate/magnesium oxide) — 125–250 mg elemental magnesium
5. Vitamin B1 (Thiamine) — 50–100 mg
6. Binder: microcrystalline cellulose (MCC)
7. Disintegrant: croscarmellose sodium (2–5%)
8. Lubricant: magnesium stearate (≤1%)
9. Glidant: colloidal silicon dioxide (≤1%)
10. Enteric coating, since gastric tolerance is a concern
11. Uses a fast-dissolving core (to achieve goal: relief within 30–60 minutes)

Geographical focus:

• Urban and semi-urban areas with high awareness and accessibility to pharmacies.
• Expansion to rural areas through NGO/health initiatives.
• Global opportunity: Menstruation is universal; hence, the product has cross-border scalability.

Development of product:

• Formulation: The above mentioned combination of natural anti-inflammatory and antispasmodic ingredients.
• Dosage form: Small, easy-to-swallow tablet with fast dissolution.
• R&D process: Partner with pharmacologists, gynecologists, and biochemists to ensure safety and efficacy.
• Clinical trials: Phase-wise testing to establish safety, absence of carcinogenic effects, and effectiveness compared to NSAIDs.

Who does this product serve?

• Women and menstruators of all ages, from teenagers to working professionals and mothers.
• It serves those seeking a safe, affordable, and effective alternative to conventional painkillers, especially for regular monthly use without harmful side effects.

Why does this matter to me?

• This product will be important to many as it tackles one of the most common yet overlooked health concerns.
• I want to provide accessible, safe and efficient period painkillers to ensure the health and the quality of life of all women.

Road Map to the Market:

• Preclinical (0–1 yr): Formulation is finalized by in vitro and animal safety/toxicity studies per ICMR/GLP guidelines.
• Clinical Trials (1–4 yrs):

1. Phase I: Small group (20–80, healthy volunteers) under CDSCO approval.
2. Phase II: 100–200 women with dysmenorrhea, multi-center hospitals.
3. Phase III: 1,000+ women across India, proving safety/efficacy.

• Regulatory Approval (2–4 yrs): Submit New Drug Application (NDA) to CDSCO / DCGI with trial data, CMC, and stability results.
• Manufacturing (3–4 yrs): Set up GMP-certified facility or partner with Indian pharma manufacturer; raw materials sourced under AYUSH/Pharma standards.
• Market Launch (4–5 yrs): Distribution via Jan Aushadhi stores, local pharmacies, and hospitals and online sales through e-pharmacy platforms (Pharmeasy, Tata 1mg).